Acurx Pharmaceuticals, Inc.: directors' dealings · United States · SEC (Form 4)

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. (ticker: ACXP) is a U.S.-listed biopharmaceutical company trading on NASDAQ, headquartered in Staten Island, New York, United States. For French-speaking investors, Acurx should be viewed as a clinical-stage antibiotic developer focused on a highly specialized but strategically important niche: difficult-to-treat bacterial infections, especially Gram-positive pathogens with significant resistance issues. The company was originally formed as a private entity and later converted into a corporation before going public in 2021. Its business model is that of a development-stage biotech rather than a commercial pharmaceutical company. As such, Acurx does not yet have a mature marketed product portfolio; instead, it concentrates resources on drug discovery, preclinical validation, and clinical development of novel antibacterial candidates. That makes the stock a classic pipeline-driven biotech story, where valuation is closely tied to clinical milestones, regulatory progress, and financing capacity. Acurx’s scientific thesis centers on inhibiting DNA polymerase IIIC (Pol IIIC), a bacterial target that the company describes as previously underexploited in medical research. Its lead program, ibezapolstat, historically referenced in earlier materials as ACX-362E, is designed for the treatment of Clostridioides difficile infection (CDI), a major healthcare-associated and community-facing infection with persistent unmet medical need. The pipeline also includes ACX-375C, aimed at other Gram-positive infections, with development efforts directed toward pathogens such as Enterococcus, including vancomycin-resistant strains (VRE), as well as methicillin-resistant Staphylococcus aureus (MRSA) and drug-resistant Streptococcus pneumoniae. In addition, the company has highlighted a computational chemistry program intended to broaden its universe of potential antibiotic candidates. From a competitive perspective, Acurx operates in a narrow field where differentiation depends on novelty of mechanism, translational data quality, and the ability to secure regulatory support. The company has disclosed favorable designations such as Qualified Infectious Disease Product (QIDP) and Fast Track eligibility for its lead program, which may improve development visibility and potential review dynamics. However, investors should also recognize the typical risks of a small-cap biotech: ongoing funding needs, clinical uncertainty, possible dilution, and a long path to any potential commercialization. Geographically, Acurx is primarily a U.S.-based company, but it has disclosed scientific collaborations outside the United States, including work with Leiden University Medical Center in Europe and earlier collaboration with WuXi AppTec. Recent notable items include annual and quarterly business updates, pipeline disclosures, and SEC filing activity, including insider transaction reporting on Form 4. In short, ACXP is a speculative healthcare name built around antibiotic innovation, with value creation dependent on clinical execution and regulatory progress rather than current sales.